Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations

Journal of Cystic Fibrosis

Volumn 14, Issue 6, 2015, Pages 770-776

  Waters, Valerie ^a   Stanojevic, Sanja ^a   Klingel, Michelle ^a   Chiang, Jackie ^a   Sonneveld, Nicole ^a   Kukkar, Richa ^a   Tullis, Elizabeth ^b   Ratjen, Felix ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Antimicrobial duration; Intravenous; Lung function

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BURKHOLDERIA CEPACIA; BURKHOLDERIA CEPACIA COMPLEX INFECTION; BURKHOLDERIA CEPACIA INFECTION; COHORT ANALYSIS; CYSTIC FIBROSIS; DISEASE EXACERBATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; INVESTIGATIVE PROCEDURES; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PULMONARY EXACERBATION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; COMPLICATION; DISEASE COURSE; LUNG DISEASES; TIME FACTOR;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; COHORT STUDIES; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG DISEASES; MALE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84946500170     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2015.07.010     Document Type: Article

References (17)

1. Liou T.G., Adler F.R., Fitzsimmons S.C., Cahill B.C., Hibbs J.R., Marshall B.C. Predictive 5-year survivorship model of cystic fibrosis. Am. J. Epidemiol. 2001, 153(4):345-352.
2. Britto M.T., Kotagal U.R., Hornung R.W., Atherton H.D., Tsevat J., Wilmott R.W. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002, 121(1):64-72.
3. Konstan M.W., Morgan W.J., Butler S.M., Pasta D.J., Craib M.L., Silva S.J., et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J. Pediatr. 2007, 151(2):134-139. [9 e1].
4. Emerson J., Rosenfeld M., McNamara S., Ramsey B., Gibson R.L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr. Pulmonol. 2002, 34(2):91-100.
5. Waters V., Stanojevic S., Atenafu E.G., Lu A., Yau Y., Tullis E., et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur. Respir. J. 2012, 40(1):61-66.
6. Waters V., Atenafu E.G., Salazar J.G., Lu A., Yau Y., Matukas L., et al. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J. Cyst. Fibros. 2012, 11(1):8-13.
7. Sanders D.B., Bittner R.C., Rosenfeld M., Hoffman L.R., Redding G.J., Goss C.H. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am. J. Respir. Crit. Care Med. 2010, 182(5):627-632.
8. VanDevanter D.R., O'Riordan M.A., Blumer J.L., Konstan M.W. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir. Res. 2010, 11:137. [PMCID: 2959026].
9. Collaco J.M., Green D.M., Cutting G.R., Naughton K.M., Mogayzel P.J. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am. J. Respir. Crit. Care Med. 2010, 182(9):1137-1143. [PMCID: 3001256].
10. Sequeiros I.M., Jarad N.A. Extending the course of intravenous antibiotics in adult patients with cystic fibrosis with acute pulmonary exacerbations. Chron. Respir. Dis. 2012, 9(4):213-220.
11. Farrell P.M., Rosenstein B.J., White T.B., Accurso F.J., Castellani C., Cutting G.R., et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J. Pediatr. 2008, 153(2):S4-S14.
12. Waters V., Yau Y., Prasad S., Lu A., Atenafu E., Crandall I., et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am. J. Respir. Crit. Care Med. 2011, 183(5):635-640.
13. Quanjer P.H., Stanojevic S., Cole T.J., Baur X., Hall G.L., Culver B.H., et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur. Respir. J. 2012, 40(6):1324-1343.
14. Waters V.J., Stanojevic S., Sonneveld N., Klingel M., Grasemann H., Yau Y.C., et al. Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. J. Cyst. Fibros. 2015, 14(6):755-762.
15. Redding G.J., Restuccia R., Cotton E.K., Brooks J.G. Serial changes in pulmonary functions in children hospitalized with cystic fibrosis. Am. Rev. Respir. Dis. 1982, 126(1):31-36.
16. Morgan W.J., Wagener J.S., Yegin A., Pasta D.J., Millar S.J., Konstan M.W. Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function. J. Pediatr. 2013, 163(4):1152-1157. [e2. PMCID: 4064589].
17. Heltshe S.L., Goss C.H., Thompson V., Sagel S.D., Sanders D.B., Marshall B.C., et al. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax 2015, [Epub ahead of print]. 10.1136/thoraxjnl-2014-206750.